The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Targeted delivery of therapeutic agents to the heart
Open accessAbstract
For therapeutic materials to be successfully delivered to the heart, several barriers need to be overcome, including the anatomical challenges of access, the mechanical force of the blood flow, the endothelial barrier, the cellular barrier and the immune response. Various vectors and delivery methods have been proposed to improve the cardiac-specific uptake of materials to modify gene expression. Viral and non-viral vectors are widely used to deliver genetic materials, but each has its respective advantages and shortcomings. Adeno-associated viruses have emerged as one of the best tools for heart-targeted gene delivery. In addition, extracellular vesicles, including exosomes, which are secreted by most cell types, have gained popularity for drug delivery to several organs, including the heart. Accumulating evidence suggests that extracellular vesicles can carry and transfer functional proteins and genetic materials into target cells and might be an attractive option for heart-targeted delivery. Extracellular vesicles or artificial carriers of non-viral and viral vectors can be bioengineered with immune-evasive and cardiotropic properties. In this Review, we discuss the latest strategies for targeting and delivering therapeutic materials to the heart and how the knowledge of different vectors and delivery methods could successfully translate cardiac gene therapy into the clinical setting. For therapeutic materials to be delivered to the heart, several barriers need to be overcome. In this Review, Ishikawa and colleagues discuss strategies for targeted delivery of therapeutic materials to the heart, including the use of adeno-associated viruses and exosomes, with a focus on agents directed at modifying gene expression. Therapies directed at modifying gene expression are emerging and have shown positive results for non-cardiac diseases in clinical trials; clinical translation of these therapies for cardiac diseases remains slow. Currently, cardiac-specific delivery of therapeutic materials in large mammals requires invasive approaches, and the patterns of distribution depend on the delivery method used. Vector options for gene delivery are increasing; adeno-associated viruses provide safe gene delivery but their gene-transduction efficacy in the human heart remains suboptimal. Extracellular vesicles hold immense potential for the delivery of therapeutic agents; their clinical applications depend on their efficient isolation, scalability, drug loading, biodistribution and tissue targeting. Next-generation cardiovascular therapeutics might include bioengineered macromolecules, viruses, nanobiologics and extracellular vesicles. Therapies directed at modifying gene expression are emerging and have shown positive results for non-cardiac diseases in clinical trials; clinical translation of these therapies for cardiac diseases remains slow. Currently, cardiac-specific delivery of therapeutic materials in large mammals requires invasive approaches, and the patterns of distribution depend on the delivery method used. Vector options for gene delivery are increasing; adeno-associated viruses provide safe gene delivery but their gene-transduction efficacy in the human heart remains suboptimal. Extracellular vesicles hold immense potential for the delivery of therapeutic agents; their clinical applications depend on their efficient isolation, scalability, drug loading, biodistribution and tissue targeting. Next-generation cardiovascular therapeutics might include bioengineered macromolecules, viruses, nanobiologics and extracellular vesicles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Regulation of immune responses by extracellular vesicles
Robbins, P. D., & Morelli, A. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3622 · Cited by 2,260
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Extracellular vesicles for drug delivery.
Vader, P., Mol, E. A., Pasterkamp, G., & Schiffelers, R. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.006 · Cited by 1,319
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
McCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735
Development of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Cited by
Gene therapy: Comprehensive overview and therapeutic applications
Sayed, N., Allawadhi, P., Khurana, A., Singh, V., Navik, U., Pasumarthi, S. K., Khurana, I., Banothu, A. K., Weiskirchen, R., & Bharani, K. K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120375 · Cited by 337
Zhou, Y., Liang, Q., Wu, X., Duan, S., Ge, C., Ye, H., Lu, J., Zhu, R., Chen, Y., Meng, F., et al. (2023) · Advanced Materials · doi:10.1002/adma.202210691 · Cited by 115
Applications of Gene Therapy in Cardiomyopathies
Argiro, A., Bui, Q., Hong, K. N., Ammirati, E., Olivotto, I., & Adler, E. (2024) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.09.015 · Cited by 59
Metadata
- Authors
- Sahoo, S., Kariya, T., & Ishikawa, K.
- Venue
- Nature Reviews Cardiology
- Published
- 2021-01-26
- Volume
- 18
- Issue
- 6
- Pages
- 389-399
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- OpenAlex
- W3121527138
- Cited by
- 159
- References
- 16
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted delivery of therapeutic agents to the heart. https://app.cochat.ai/papers/10.1038/s41569-020-00499-9
- The paper
- Sahoo, S., Kariya, T., & Ishikawa, K. (2021). Targeted delivery of therapeutic agents to the heart. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-020-00499-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.